Advertisement OccuLogix sells Solx subsidiary - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

OccuLogix sells Solx subsidiary

Canada-based OccuLogix has sold its Solx subsidiary to a company owned by that subsidiary's president and founder, Doug Adams.

Under the terms of the purchase agreement, the acquirer assumed all costs and liabilities of Solx as of December 1, 2007, in addition to a $5 million payment obligation owed by OccuLogix to the former shareholders of Solx, due on September 1, 2008.

In addition, the purchase agreement provides that OccuLogix will receive a royalty of 3% of revenues generated by world-wide sales of the Solx 790 Laser and the Solx Gold Shunt, until such time as Solx becomes cash-flow positive from its operations, and a royalty of 5% thereafter. Both the Solx 790 Laser and the Solx Gold Shunt have CE approval in Europe and are currently the subject of two randomized, multi-center studies in the US.